(E)-methyl 3-(4-(benzyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)acrylate

ID: ALA3895447

Chembl Id: CHEMBL3895447

PubChem CID: 118236938

Max Phase: Preclinical

Molecular Formula: C17H15N3O3

Molecular Weight: 309.32

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COC(=O)/C=C/c1c[nH]c2ncnc(OCc3ccccc3)c12

Standard InChI:  InChI=1S/C17H15N3O3/c1-22-14(21)8-7-13-9-18-16-15(13)17(20-11-19-16)23-10-12-5-3-2-4-6-12/h2-9,11H,10H2,1H3,(H,18,19,20)/b8-7+

Standard InChI Key:  DSQSRIOQMWVLNQ-BQYQJAHWSA-N

Alternative Forms

1. Parent:

   

   ALA3895447

   methyl (E)-3-(4-phenylmethoxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)prop-2-enoate

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 309.32

Molecular Weight (Monoisotopic): 309.1113

AlogP: 2.72

#Rotatable Bonds: 5

Polar Surface Area: 77.10

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.63

CX Basic pKa: 4.98

CX LogP: 3.22

CX LogD: 3.22

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.58

Np Likeness Score: -0.35

References

1.  (2014)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment, 

2.  (2016)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment, 

Source

Source(2):

• BindingDB Database
• Patent Bioactivity Data